This article has multiple issues. Please help improve it or discuss these issues on the talk page . (Learn how and when to remove these messages)
|
Chris Goodnow | |
---|---|
Born | Hong Kong |
Alma mater | |
Scientific career | |
Institutions |
Christopher Carl Goodnow (born 19 September 1959) is an immunology researcher and the current executive director of the Garvan Institute of Medical Research. He holds the Bill and Patricia Ritchie Foundation Chair and is a Conjoint Professor in the faculty of medicine at UNSW Sydney. He holds dual Australian and US citizenship.
Born in Hong Kong in 1959 to Robert Goodnow and Jacqueline J. Goodnow AC, Goodnow grew up in Rome and Washington DC before moving to Sydney, Australia as a teenager. [1] He trained in veterinary medicine and surgery, immunochemistry and immunology at the University of Sydney and in DNA technology at Stanford University. After doctoral studies at Melbourne's Walter and Eliza Hall Institute of Medical Research and the University of Sydney, he joined the faculty of the Stanford University Medical School and the Howard Hughes Medical Institute in 1990. [2] There he established the concept of multiple immune tolerance checkpoints, a framework now widely used in cancer treatment with "checkpoint inhibitors", and revealed the function of key genes in these checkpoints. [3]
In 1997 Goodnow joined the faculty at the Australian National University as professor and founding director of the Medical Genome Centre, leading its development into a major national research facility, the Australian Phenomics Facility. In 2015 he joined the Garvan Institute of Medical Research as deputy director to translate genomic DNA sequence analysis of the human immune system into understanding the cause of immune disorders and developing more effective, personalised treatments. [2] During this period Goodnow oversaw the development of the Garvan-Weizmann Centre for Cellular Genomics in partnership with the Weizmann Institute of Science in Israel, [4] [5] the only multidisciplinary centre of its kind in the southern hemisphere as well as playing a key role in the development of the Clinical Immunogenomics Research Consortium Australia (CIRCA). [6] In May 2018, Goodnow was named Executive Director of the Garvan Institute. [7]
Goodnow is well known for leading a 1980 expedition to Indonesia's remote Mentawai Islands off the coast of Sumatra, discovering the now-famous surf breaks and a wave that is today considered one of the world's best, Macaronis. [19] [20] [21] [22]
Sir Gustav Victor Joseph Nossal is an Austrian-born Australian research biologist. He is famous for his contributions to the fields of antibody formation and immunological tolerance.
John Shine is an Australian biochemist and molecular biologist. Shine and Lynn Dalgarno discovered a nucleotide sequence, called the Shine–Dalgarno sequence, necessary for the initiation of protein synthesis. He directed the Garvan Institute of Medical Research in Sydney from 1990 to 2011. From 2018 to 2022, Shine was President of the Australian Academy of Science.
Ian Hector Frazer is a Scottish-born Australian immunologist, the founding CEO and Director of Research of the Translational Research Institute (Australia). Frazer and Jian Zhou developed and patented the basic technology behind the HPV vaccine against cervical cancer at the University of Queensland. Researchers at the National Cancer Institute, Georgetown University, and University of Rochester also contributed to the further development of the cervical cancer vaccine in parallel.
St Vincent's Hospital, Sydney is a leading tertiary referral hospital and research facility located in Darlinghurst, Sydney. Though funded and integrated into the New South Wales state public health system, it is operated by St Vincent's Health Australia. It is affiliated with the University of Tasmania College of Health and Medicine and the University of New South Wales Medical School.
Dame Bridget Margaret Ogilvie, is an Australian and British scientist.
The Garvan Institute of Medical Research is an Australian biomedical research institute located in Darlinghurst, Sydney, New South Wales. Founded in 1963 by the Sisters of Charity as a research department of St Vincent's Hospital, it is now one of Australia's largest medical research institutions, with approximately 750 scientists, students and support staff.
Michael Sela was an Israeli immunologist of Polish Jewish origin. He was the W. Garfield Weston Professor of Immunology at the Weizmann Institute of Science in Rehovot. He was a president of the Weizmann Institute of Science.
Robert Llewellyn Clancy is a retired Australian clinical immunologist in the field of mucosal immunology. He is known for his research and development of therapies for chronic obstructive pulmonary disease (COPD), commonly known as emphysema.
John Stanley Mattick is an Australian molecular biologist known for his efforts to assign function to non-coding DNA. Mattick was the executive director of the Garvan Institute of Medical Research from 2012 to 2018. He joined Genomics England in May 2018 as chief executive officer. In October 2019, he joined the University of New South Wales in Sydney.
James Patrick Allison is an American immunologist and Nobel laureate who holds the position of professor and chair of immunology and executive director of immunotherapy platform at the MD Anderson Cancer Center in Houston, Texas. Allison is Regental Professor and Founding-Director of James P. Allison Institute at the MD Anderson Cancer Center.
Vanessa Hayes is a geneticist conducting research into cancer genomics and comparative human genomics. She leads a research group at the Garvan Institute of Medical Research in Sydney Australia and holds the Petre Chair of Prostate Cancer Research at the University of Sydney.
David Albert Cooper was an Australian HIV/AIDS researcher, immunologist, professor at the University of New South Wales, and the director of the Kirby Institute. He and Professor Ron Penny diagnosed the first case of HIV in Australia.
The ANU College of Health & Medicine is an Australian university college for the study of medicine, psychology, mental health, epidemiology and population health at the Australian National University (ANU), located in Canberra, the capital city of Australia.
Misty Rayna Jenkins is an Australian scientist known for her research into lymphocytes and cancer treatment.
Georgina Venetia Long is an Australian medical oncologist, clinical trialist and translational researcher, and works in drug therapy development. She was the joint recipient of the National Australia Day Council's 2024 Australian of the Year Award.
Jessica Geraldine Borger is an Australian T Cell immunologist, lecturer and graduate course coordinator at the Central Clinical School, Monash University. Her research has added to the understanding of the molecular mechanisms of T cell function. Additionally, Borger is a news and commentary editor for Immunology & Cell Biology and a guest associate editor for Frontiers in Immunology, and a reviewer for several academic journals. Borger also advocates for gender equality in science, technology, engineering and mathematics (STEM) in her position a member of the Gender Equity, Diversity and Inclusion committee of the Central Clinical School at Monash University.
Laura K. Mackay is an Australian immunologist and Professor of Immunology at the University of Melbourne. Mackay is the Theme Leader in Immunology and Laboratory Head at the Peter Doherty Institute for Infection and Immunity. In 2022, she was the youngest Fellow elected to the Australian Academy of Health and Medical Sciences.
Fabienne Mackay is a French Australian research immunologist and institutional leader within the Australian medical research, education and innovation sectors. She is the Director and CEO of the QIMR Berghofer Medical Research Institute since 2020, after being the inaugural Head of the School of Biomedical Sciences at the University of Melbourne during the preceding five years. She is also an Honorary Professor at the Faculties of Medicine of the University of Queensland and the University of Melbourne. Her work has attracted public attention for its contribution to the pathophysiological understanding and treatment of lupus and other autoimmune diseases. Mackay has been notably awarded, achieving international reputation for her widely cited research describing B-cell activating factor (BAFF) and other cytokines of the TNF receptor superfamily, and their roles in B cell physiology, autoimmunity and cancer. She is an elected Fellow of the Australian Academy of Health and Medical Sciences.
Maree Gleeson is an Australian immunologist. Her research has focused on respiratory immunology in children and elite athletes. She has held multiple leadership positions within the health sector in the Hunter Region in NSW.
Alessandra Alberta Pucci is an Australian immunologist and entrepreneur who founded and led Australian Monoclonal Development, the first biotechnology company in Australia.